Mineralys Therapeutics Says Lorundrostat Showed 'Significant' Decline in Systolic Blood Pressure in Hypertension Phase 2 Trial

MT Newswires ·  09/11/2023 16:08
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment